1. Home
  2. GKOS vs WAL Comparison

GKOS vs WAL Comparison

Compare GKOS & WAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • WAL
  • Stock Information
  • Founded
  • GKOS 1998
  • WAL 1994
  • Country
  • GKOS United States
  • WAL United States
  • Employees
  • GKOS N/A
  • WAL N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • WAL Major Banks
  • Sector
  • GKOS Health Care
  • WAL Finance
  • Exchange
  • GKOS Nasdaq
  • WAL Nasdaq
  • Market Cap
  • GKOS 5.1B
  • WAL 7.3B
  • IPO Year
  • GKOS 2015
  • WAL 2005
  • Fundamental
  • Price
  • GKOS $93.79
  • WAL $70.98
  • Analyst Decision
  • GKOS Strong Buy
  • WAL Strong Buy
  • Analyst Count
  • GKOS 13
  • WAL 15
  • Target Price
  • GKOS $155.00
  • WAL $95.33
  • AVG Volume (30 Days)
  • GKOS 1.0M
  • WAL 1.6M
  • Earning Date
  • GKOS 04-30-2025
  • WAL 04-21-2025
  • Dividend Yield
  • GKOS N/A
  • WAL 2.13%
  • EPS Growth
  • GKOS N/A
  • WAL 6.13
  • EPS
  • GKOS N/A
  • WAL 7.28
  • Revenue
  • GKOS $383,481,000.00
  • WAL $3,049,400,000.00
  • Revenue This Year
  • GKOS $27.84
  • WAL $13.39
  • Revenue Next Year
  • GKOS $27.99
  • WAL $9.74
  • P/E Ratio
  • GKOS N/A
  • WAL $9.79
  • Revenue Growth
  • GKOS 21.85
  • WAL 11.37
  • 52 Week Low
  • GKOS $77.91
  • WAL $56.70
  • 52 Week High
  • GKOS $163.71
  • WAL $98.10
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 46.82
  • WAL 51.60
  • Support Level
  • GKOS $92.79
  • WAL $62.38
  • Resistance Level
  • GKOS $97.38
  • WAL $71.39
  • Average True Range (ATR)
  • GKOS 4.43
  • WAL 3.65
  • MACD
  • GKOS 1.61
  • WAL 1.22
  • Stochastic Oscillator
  • GKOS 72.39
  • WAL 94.27

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About WAL Western Alliance Bancorporation (DE)

Western Alliance Bancorporation is a Las Vegas-based holding company with regional banks operating in Nevada, Arizona, and California. The bank offers retail banking services and focuses on mortgages for retail customers and commercial loans. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.

Share on Social Networks: